Clinical Trial: INSL3 as a Biomarker of Pubertal Activation: Role in Evaluating Precocious and Delayed Puberty

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07859787) titled 'INSL3 as a Biomarker of Pubertal Activation: Role in Evaluating Precocious and Delayed Puberty' on Sept. 30.

Brief Summary: This is an observational study in children up to 16 years old who are suspected of having central precocious puberty or delayed puberty. The main questions it aims to answer are:

* Can the level of insulin-like peptide 3 (INSL3) predict if a child's puberty has truly started?

* Can this marker help reduce the need for more complex and invasive tests?

Participants will:

* Give one extra blood sample just before starting the standard gonadotropin-releasing hormone (GnRH) stimulation test (during the baseline b...